Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Inclusion criteria:

- Relapsed or refractory de novo classical Hodgkin lymphoma

- Participant may have failed to achieve a response to, progressed after, or be
ineligible for autologous stem cell transplant (auto-SCT)

- Participant may have failed to achieve a response or progressed after treatment with
brentuximab vedotin or may be brentuximab vedotin naïve

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Measurable disease

- Adequate organ function

Exclusion criteria:

- Diagnosis of immunosuppression or receiving systemic steroid therapy or any other
form of immunosuppressive therapy within 7 days prior to the first dose of study
medication

- Prior monoclonal antibody within 4 weeks prior to study Day 1 or chemotherapy,
targeted small molecular therapy, or radiation therapy within 2 weeks prior to study
Day 1

- Prior allogeneic hematopoietic stem cell transplantation

- Known clinically active central nervous system involvement

- Known additional malignancy that is progressing or requires active treatment

- Has a known history of Human Immunodeficiency Virus (HIV)

- Has known active Hepatitis B (HBV) or Hepatitis C (HCV)

- Active autoimmune disease requiring systemic treatment in past 2 years

- Evidence of active, non-infectious pneumonitis